New hope for myeloma: targeted drug combo faces off against standard care

NCT ID NCT06868667

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Apr 23, 2026 · Last updated May 15, 2026 · Updated 3 times

Summary

This study compares two drug combinations for people with multiple myeloma that has returned or stopped responding to treatment. One group gets belantamab mafodotin plus standard drugs, the other gets daratumumab plus standard drugs. The goal is to see which combo works better at delaying cancer growth. About 24 Japanese adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Aomori, Japan
GSK Investigational Site

Fukuoka, Japan
GSK Investigational Site

Himeji, Japan
GSK Investigational Site

Kamakura, Japan
GSK Investigational Site

Kitakyushu, Japan
GSK Investigational Site

Kochi, Japan
GSK Investigational Site

Matsuyama, Japan
GSK Investigational Site

Nagoya, Japan
GSK Investigational Site

Okayama, Japan
GSK Investigational Site

Osaka, Japan
GSK Investigational Site

Ōgaki, Japan
GSK Investigational Site

Shibukawa, Japan
GSK Investigational Site

Sunto-gun, Japan
GSK Investigational Site

Suwa, Japan
GSK Investigational Site

Toyohashi, Japan
GSK Investigational Site

Yokohama, Japan

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA